A new treatment option for the very rare condition infantile onset 5q spinal muscular atrophy (type I SMA) is among five medicines that have been endorsed by Scottish cost regulators for use on the NHS. More: Five therapies endorsed for
read moreCost regulators for the NHS are recommending that three new types of treatment for people with blood cancer are made available on the NHS England and Wales. More: NICE OKs three new therapies for blood cancer Source: News
read moreUS regulators are undertaking a priority review of Roche unit Genentech’s PD-L1 inhibitor Tecentriq, in combination with Avastin and standard chemotherapy for some patients with lung cancer. More: First-line use of Roche’s Tecentriq given priority review Source: News
read moreJanssen’s Darzalex has become the first monoclonal antibody to be approved in the US to treat patients newly diagnosed with multiple myeloma. More: Darzalex combo wins nod for newly diagnosed multiple myeloma Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals